TRIUMPH-3 tracked cardiovascular events specifically (MACE), finding no statistically significant difference from placebo neither harm nor confirmed benefit
Novo Nordisk is currently investigating two amylin agonists, as well as oral [SC20] amycretin (NCT06049329 12 ) and subcutaneous amycretin (NCT06064006 13 ) a long-acting co-agonist of GLP-1 and amylin
The main differences are the maker, the pen or vial format, and the price
Garvey: Yeah, well, I think that the foremost aspect of this is the efficacy
The glucose-dependent nature of tirzepatide's mechanism means that insulin secretion diminishes as blood glucose normalizes, which reduces the risk of hypoglycemia compared to insulin secretagogues or exogenous insulin therapy
The question of how long peptides last in the fridge is not a simple one, and the answer depends on factors most people never consider